Novo Nordisk's new weight-loss pill meets main goal in late-stage diabetes study
诺和诺德诺和诺德(US:NVO) Reuters·2026-04-23 17:23

诺和诺德口服GLP-1药物临床研究结果 - 诺和诺德的口服GLP-1药物在一项针对10至17岁儿童和青少年2型糖尿病患者的后期研究中达到了主要目标 [1] 药物研发进展 - 该口服GLP-1药物的晚期临床研究取得了积极结果 [1]

Novo Nordisk's new weight-loss pill meets main goal in late-stage diabetes study - Reportify